IBIO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Mai 2024 @ 21:21):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
Tagesvolumen	134 797
Durchschnittsvolumen	3.96M
Marktkapitalisierung	15.75M
EPS	$0 ( 2024-02-13 )
Nächstes Ertragsdatum	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0160 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Duran Felipe	Buy	35 800	Stock Option (right to buy)
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock

INSIDER POWER
85.79
Last 90 transactions
Buy: 50 021 245 \| Sell: 29 398 433

Volumen Korrelation

Lang: -0.01 (neutral)

Kurz: 0.14 (neutral)

Signal:(44.768) Neutral

Ibio Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Ibio Inc Korrelation - Währung/Rohstoff

0.76
( moderate )

0.87
( strong )

0.51
( weak )

-0.74
( moderate negative )

-0.93
( very strong negative )

Ibio Inc Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2023
Umsatz:	$0
Bruttogewinn:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2022
Umsatz:	$2.38M
Bruttogewinn:	$2.17M (90.94 %)
EPS:	$-2 924.26

FY	2021
Umsatz:	$2.37M
Bruttogewinn:	$909 000 (38.34 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.